We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Science Group Plc | SAG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 11.00 | 2.58% | 438.00 | 15:19:58 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 427.00 | 427.00 | 438.00 | 438.00 | 427.00 |
| Industry Sector |
|---|
| SUPPORT SERVICES |
| Top Posts |
|---|
Posted at 21/3/2024 08:42 by eigthwonder Ratcliffe has a nose for cheap companies but has a very high opinion of himself and a very low opinion of everyone else. Don’t feel too hard done by as PIs, he doesn’t care much for institutional investors either. I think the quote is as much about his ego rather than sharing the journey with others. |
Posted at 21/3/2024 08:25 by nchanning Could easily see Frontier return to making a few million operating profit a year which would really make the shares look stupidly cheap. Don't think management should moan about the low valuation until they make an effort to engage with private shareholders. Really not too much to ask to do an investor meet company presentation every six months . 2024 Forecasts look very beatable , perhaps upgrades to follow in broker note shortly . |
Posted at 15/12/2022 13:19 by truffle The free float is still relatively small as far as I recall. If an investor wants to build a position he has to be patient and/or pay up. |
Posted at 24/8/2021 14:51 by larry laffer mammyokoSensible decision. I’m a long term TPG investor and as a company they have never served the PI very well. IMHO Carthorse ran the company to suit himself and his pension fund. He treated any PI with complete contempt, he had history in that area. Going back to his days at Rangers football club. It maybe SAG can extract some value from the assets. Good luck either way. |
Posted at 14/7/2021 07:28 by illiswilgig It's unfortunate certainly. No recruitment process can be perfect. All succeed to a greater or lesser extent on occasion.Given the stake owned by the founding CEO this resembles an owner managed firm than an FTSE company and it probably says more about the expectations of the CEO than it does the recruitment process. The only thing worse than hiring the wrong person is failing to address the mistake. Boards do this far too often for my liking. In this case I am impressed that it's been addressed swiftly and conclusively. The culture of a firm managed by the founder who retains a large stake is not to all investors liking. It is something I look for, but it can be an interesting ride, cheers |
Posted at 06/11/2020 09:28 by hazl Headline12/10/2020 11:21 ALNC Science Group Anticipates 2020 Profit Ahead Of Expectations 12/10/2020 06:00 UKREG Science Group PLC Trading Update 08/10/2020 06:00 UKREG Science Group PLC Issue of share options & PDMR dealing 05/10/2020 06:00 UKREG Science Group PLC TR1: Notification of Major Interest in Shares 01/10/2020 10:15 UKREG Science Group PLC TR1: Notification of Major Interest in Shares 30/09/2020 14:59 ALNC UK DIRECTOR DEALINGS SUMMARY: Science Group Chair Sells 4.8% Stake 30/09/2020 13:30 UKREG Science Group PLC Director Dealing & Exercise of Share Options With Headlines like this I tend to agree. |
Posted at 04/3/2015 08:08 by battlebus2 Still a clear under valuation imv.. I also believe it's likely we will see a new institutional investor. |
Posted at 04/3/2015 07:56 by battlebus2 Results out. As expected with the difficult currency headwinds.Second half back to growth. Cash balances worth 86p 4P dividend and a buy back of up to 10% of the shares in issue, this may be used to facilitate an institutional investor to gain a holding due to lack of liquidity at present Still on the look out for acquisitions. Summary In summary, 2014 had a more challenging start than the prior year which, as previously reported, had been exceptionally strong. This was made more difficult by a rapidly deteriorating foreign exchange environment in the first half. However the second half of the year saw a return to organic growth in the core consultancy business, despite the negative currency impact. Through tight cost control, operating margins were above the Board's target and a satisfactory overall result for the year was achieved. The integration of OTM Consulting, acquired in mid-2013, has been successful and the integration of Oakland is now in progress. The Board continues to evaluate corporate opportunities to accelerate the growth of Sagentia, although there can be no certainty that any transaction(s) will occur. In the absence of a major acquisition, the Board has considered how best to deliver value for Shareholders and is proposing specific measures, namely a very attractive dividend, increased share buy-back programme and supply side liquidity. Shareholders will have the opportunity to vote on these proposals at the Annual General Meeting, scheduled for 21 May 2015. |
Posted at 18/2/2015 12:34 by battlebus2 Great to see another tick up, mustn't be far from some news imv..17 February 2015 We recently attended the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco. This month, Sagentia’s VP of Surgical, Alistair Fleming, reflects on some of the major themes and topics highlighted during the event. Perhaps unsurprisingly, data proved to be a frequent talking point at this year’s conference, with ‘information liquidity’ being a key theme, but what does this phrase mean? In the past, a lack of data stood in the way of better care. Now the opposite is true: healthcare is inundated with data. We have electronic patient records, tracking data on patient condition, co-morbidities and changes in scientific flow to give just a few examples. With this new wealth of data the healthcare industry is witnessing the emergence of an array of new services. These services are designed to enable ‘information liquidity’: streamline workflow, make data seamlessly available anywhere and at any time through easy but secure, sharing and storage. One example offered at the conference focused around the area of Bioinformatics. Illumina’s BaseSpace, which has been developing over the past few years and is touted as the world’s largest genomics cloud with 125,000 runs of customer test data is a cloud computing environment for next-generation sequencing (NGS) data analysis and management. BaseSpace is designed to be flexible, available in both cloud and onsite solutions. The aim is to allow sequencing labs to easily and securely analyse, archive, and share sequencing data. Researchers can then simplify and accelerate NGS data analysis with push-button tools. BaseSpace is gathering interest from both customers and collaborators, but there are still many developments planned for the system and, as healthcare data services advance, we expect the field of Bioinformatics to receive increasing attention at investor updates over the next couple of years. The opportunities for liquid biopsies – non-invasive blood tests for tumour diagnosis – and the recent advancements in genetic sequencing and molecular diagnosis, were also highlighted during the week’s proceedings. It is now possible to learn a great deal about what is occurring in a person’s body by testing a blood sample, a significantly less invasive method of investigation. While developments in the non-invasive pre-natal diagnostic market are well documented (including our client Premaitha), the applications for this approach in oncology are truly exciting and could transform clinical practice. Indicative signs in a sample of blood may help physicians detect cancerous tumours located elsewhere in the body. The current methods rely upon symptomatic presentation and imaging followed by tissue biopsies, which are costly, invasive and by definition only pick up a relatively progressed disease state. Liquid biopsies would minimise the need for hospital admissions and biopsy surgery for the patient, and could also enable more early-stage diagnosis, potentially to be carried out at home. Finally, with the increased IPO and M&A activity experienced in 2014, attendees at the conference were bolstered by the news that confidence has returned and investors expect 2015 to see even higher levels of activity in these areas. The recent merger between Covidien and Medtronic was still causing a buzz and demonstrates the possibilities that such synergies can bring to the whole care pathway. For example, companies might provide products for use by surgeons in the operating room, as well as supplying services to patients post-operatively. Through the pooling of resources, this situation offers the potential to spread costs among all of the suppliers in the care pathway. More intriguingly however, the combined group has the ability to redistribute cost and associate value derived at one stage in the care pathway with cost incurred elsewhere. This could have significant benefit for both suppliers and patients. Cost efficiencies would be achieved by the suppliers, which could then be passed on to patients in the form of improved procedures and outcomes. In all, it feels like 2015 starts with much promise and buzz in the industry. New technologies are driving innovation not just in products, but in services and business models in ways that could fundamentally transform the industry in coming years. Given the pressures on healthcare provision, this is welcome news. |
Posted at 27/3/2014 12:59 by truffle You're probably not missing anything. Its a good company, run by an excellent Chairman, and making consistently steady progress so it would seem. Check the past 3/4 years growth. However, it seems to remain under the radar of most investors so not much BB activity, but that's not necessarily a bad thing. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
